Merrimack Pharmaceuticals Story Overview

MACK -- USA Stock  

USD 5.67  0.20  3.66%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance.
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 47.90% .

Similar stores for Merrimack Pharmaceuticals

Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 in Non-Small ...businessinsider News
Markets InsiderFull coverage
over two weeks ago at http://cardinalweekly.com 
Fcb Finl Hldgs Cl A Shareholder MR Capital Management Boosted Its Stake by 1.40 Million Fil LTD Has ...
news
The Cardinal Weekly Full coverage
over three weeks ago at http://ztribune.com 
Alecta Pensionsforsakring Omsesidigt Trimmed Rockwell Automation Position Monroe Capital Shorts ...
news
Z TribuneFull coverage
over three weeks ago at http://cardinalweekly.com 
As PgE Market Value Rose, Newtyn Management Has Increased Position Gabelli Divd Income Tr GDV ...
news
The Cardinal Weekly Full coverage
Infinity Pharmaceuticals Appoints Samuel Agresta, MD, MPH as Chief Medical Officerbusinessinsider News
Markets InsiderFull coverage
over a month ago at http://www.zacks.com 
Is a Beat in the Cards for Merrimack in Q2 Earnings
zacks News
Zacks.comFull coverage
over a month ago at http://news.cmlviz.com 
Stock Volatility Risk Alert Merrimack Pharmaceuticals Inc Price Volatility Hits An Elevated Level
news
CML NewsFull coverage
over two months ago at http://nysewired.com 
What Are Analysts Saying Merrimack Pharmaceuticals, Inc.
wired  News
NYSE WIRED Full coverage
over two months ago at http://www.reuters.com 
Ex-biopharmaceutical employees convicted in US of insider trading
reuters
ReutersFull coverage
over two months ago at http://www.law360.com 
Insider-Trading Suspect Says He Lied To Friend, Not Feds
news
Law360Full coverage
over three months ago at www.macroaxis.com 
Acquisition by John Dineen of 7000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3
over three months ago at http://malibureport.com 
Is Merrimack Pharmaceuticals, Inc. a Buy The Stock Rises Again
news
The Malibu ReportMerrimack Pharmaceuticals, Inc. Increases to 8.29 on Apr, 7 US Index LiveMerrimack Pharmaceuticals Inc. Shares Rating Upgrade by Vetr Inc. BangaloreWeeklyFull coverage
over six months ago at http://ledgergazette.com 
-0.28 EPS Expected for Merrimack Pharmaceuticals Inc This Quarter
news
The Ledger Gazette - Feb 24, 2018 Merrimack Pharmaceuticals logo Wall Street analysts forecast that Merrimack Pharmaceuticals Inc will announce earnings per share of for the current quarter, Zacks reports.

EBITDA

EBITDA Comparative Analysis

  EBITDA 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in ebitda category among related companies. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Peers

Merrimack Pharmaceuticals Related Equities

DNLI  13.70 %   
0%
100.0%
DMPI  3.50 %   
0%
25.0%
EDGE  2.13 %   
0%
15.0%
NK  1.64 %   
0%
12.0%
CO  0.46 %   
3.0%
0%
DOVA  0.49 %   
3.0%
0%
EARS  1.39 %   
10.0%
0%
DVAX  2.05 %   
14.0%
0%
DRNA  3.6 %   
26.0%
0%
Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Search macroaxis.com